Theravance Biopharma

Yahoo Finance • last month

Theravance Biopharma stock rating reiterated at Buy by BTIG

Investing.com - Theravance Biopharma (NASDAQ:TBPH) received a reiterated Buy rating from BTIG, which maintained its $25.00 price target on the stock. The target represents significant upside potential from the current price of $13.80, with... Full story

Yahoo Finance • last month

Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout

Earnings Call Insights: Theravance Biopharma, Inc. (TBPH) Q2 2025 MANAGEMENT VIEW * CEO Rick E. Winningham highlighted "an excellent quarter, underscored by disciplined execution across our commercial and development organizations, whi... Full story

Yahoo Finance • last month

Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples

Introduction & Market Context Theravance Biopharma (NASDAQ:TBPH) presented its second quarter 2025 financial results on August 12, showing significant improvement from its first quarter performance. The company’s stock closed at $11.40, u... Full story

Yahoo Finance • 2 months ago

Theravance Biopharma SVP Farnum sells $113,869 in stock

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (NASDAQ:TBPH), sold 10,000 shares of company stock on July 14, 2025, according to a recent SEC Filing. The sales, executed in three separate transactions, fetched a t... Full story

Yahoo Finance • 2 months ago

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma

Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maint... Full story

Yahoo Finance • 3 months ago

Theravance higher as China approves Viatris-partnered COPD therapy

[Wooden Approved Stamp] kemalbas Theravance Biopharma (NASDAQ:TBPH [https://seekingalpha.com/symbol/TBPH]) added ~7% in the premarket on Thursday after the company announced that China approved its Viatris (NASDAQ:VTRS [https://seekingalp... Full story

Yahoo Finance • 3 months ago

China approves Theravance's YUPELRI for COPD treatment

DUBLIN - China’s National Medical Products Administration (NMPA) has approved YUPELRI (revefenacin) inhalation solution as the first once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pu... Full story

Yahoo Finance • 4 months ago

Theravance and Mylan settle patent dispute with Eugia Pharma

[Close-up of accusation and protection sides with juridical documents] AnnaStills Theravance Biopharma (NASDAQ:TBPH [https://seekingalpha.com/symbol/TBPH]) and partner Mylan reached a settlement agreement with Eugia Pharma over a patent d... Full story

Yahoo Finance • 2 years ago

12 High Growth Value Stocks to Buy According to Seth Klarman

In this article, we will take a look at the 12 high growth value stocks to buy according to Seth Klarman. To see more such companies, go directly to 5 High Growth Value Stocks to Buy According to Seth Klarman. Following clear signals from... Full story

Yahoo Finance • 2 years ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

DUBLIN, April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET (12:45 pm PT/8:45 pm IST). Theravance Biopharma Logo (... Full story

Yahoo Finance • 3 years ago

Top Healthcare Stocks for March 2023

Top healthcare stocks include Theravance Biopharma for best value, Signify Health for fastest growth, and TransMedics Group for most momentum. Continue reading... Full story

Yahoo Finance • 3 years ago

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review

Despite Months of Private Engagement From Irenic and Presumably Other Investors, Chairman & CEO Rick E. Winningham and Theravance’s Board Refuse to Act in Shareholders’ Best Interests Notes Theravance’s Total Shareholder Returns are -50%... Full story

Yahoo Finance • 3 years ago

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets

Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (n... Full story

Yahoo Finance • 3 years ago

Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022

DUBLIN, Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022. An accompanying conference c... Full story

Yahoo Finance • 3 years ago

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Further diversifies Royalty Pharma’s portfolio with market-leading respiratory therapy Expected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc... Full story

Yahoo Finance • 3 years ago

Certara Appoints Eran Broshy as New Independent Board Member

PRINCETON, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022. His appointment brings... Full story

Yahoo Finance • 3 years ago

NICE and Deutsche Telekom Global Business Announce Comprehensive Partnership to Bring the Power of CXone to Enterprises Across Europe

The alliance enables companies across the continent to deliver frictionless, digital self-service and agent-assisted experiences with CXone HOBOKEN, N.J., April 13, 2022--(BUSINESS WIRE)--NICE (Nasdaq: NICE) today announced a partnership... Full story

Yahoo Finance • 3 years ago

NICE Actimize Positioned as Highest-Scoring Vendor Across Technology Excellence Metrics in 2022 Quadrant Knowledge Anti-Money Laundering Report

Using AI and Machine Learning, NICE Actimize’s solution optimizes detection models and uses predictive analytics to identify and prioritize suspicious alerts HOBOKEN, N.J., April 12, 2022--(BUSINESS WIRE)--NICE Actimize, a NICE (NASDAQ: N... Full story